News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
LEADS BIOLABS-B (09887.HK) Partner Dianthus Selects Three Priority Indications for LBL-047, Including Sjogren's Syndrome and Lupus
LEADS BIOLABS-B (09887.HK) announced that its partner Dianthus Therapeutics has selected Sjogren's syndrome, systemic lupus erythematosus and dermatomyositis as the first three pri...
Reset
Send
The window will close in 5 seconds
LEADS BIOLABS-B (09887.HK) Partner Dianthus Selects Three Priority Indications for LBL-047, Including Sjogren's Syndrome and Lupus
Close
Recommend
1
Positive
2
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get Level 1 Real-Time Streaming!

LEADS BIOLABS-B (09887.HK)  -6.000 (-7.958%)    Short selling $918.18K; Ratio 1.089%   announced that its partner Dianthus Therapeutics has selected Sjogren's syndrome, systemic lupus erythematosus and dermatomyositis as the first three priority indications for the clinical development of LBL-047.

As a core pipeline asset under strategic focus, Dianthus is advancing the clinical development of LBL-047 to validate its clinical value in SjD, SLE and DM, three indications with significant unmet medical needs. In March 2026, Dianthus successfully completed an upsized underwritten public offering, raising gross proceeds of approximately USD719 million, providing solid capital support for the global development of LBL-047. A two-part Phase I clinical trial conducted in China was initiated in December 2025, enrolling healthy volunteers (Part A) and patients with systemic lupus erythematosus (Part B). Top-line data from healthy volunteers are expected to be released in 2H26. Upon completion of the Phase I study, Dianthus will update its clinical development plan for the priority indications. (ec/w)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-13 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.